Haleon PLC

Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

Haleon upped its forecast for profit growth this year after a strong performance from its power brands Sensodyne, parodontax and Centrum in the first six months. The consumer brands giant now expects organic profits to rise by a ‘high single-digit percentage', compared to previous guidance of ‘ahead of' the revenue forecast of  4-6%.

Haleon ups profit guidance as power brands deliver

Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a boost from its blue-chip partner Haleon PLC (LSE:HLN, NYSE:HLN) on the timing of the US roll-out of Eroxon, Futura's fast-acting gel for erectile dysfunction. In its results statement earlier Thursday, the consumer products giant said Eroxon would be available Stateside before the year-end.

Futura Medical: Haleon ready launch Eroxon in the US before the year-end

Consumer healthcare firm Haleon on Thursday forecast high single-digit growth for its 2024 organic operating profit, after it posted a 4% rise in half-year pre-tax earnings amid strong demand for its oral care products and vitamins.

Haleon sees high single-digit growth for annual organic operating profit

LeMaitre Vascular

Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?

HLN vs. LMAT: Which Stock Is the Better Value Option?

Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility' this year, suggests broker Jefferies. From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.

Haleon to quieten 'noise' with latest update, broker suggests

British consumer healthcare company Haleon said on Wednesday it would sell its nicotine replacement therapy business outside the United States to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million).

Haleon to sell nicotine replacement therapy business outside US for $633 mln

BOSTON , June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (LSE / NYSE: HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company.

Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition

GlaxoSmithKline

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.

GSK confirms exit of Haleon stake for £3.9 billion

GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.

GSK raises $1.5 bln from offloading Haleon stake at a discount

British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.

GSK intends to sell its remaining stake in Haleon

Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100 healthcare company, has seen £150 million of its shares shorted by Marshall Wace, the hedge fund. It represents the first time a short-seller of Haleon has made its position known since the company was spun out by pharma giant GSK two years ago.

Haleon faces first short seller in Marshall Wallace

Haleon plc (NYSE:HLN ) Q1 2024 Earnings Conference Call May 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Head, Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Rashad Kawan - Morgan Stanley Guillaume Delmas - UBS David Hayes - Jefferies Iain Simpson - Barclays Bruno Monteyne - Bernstein Victoria Petrova - Bank of America Celine Pannuti - JPMorgan Tom Sykes - Deutsche Bank Mikheil Omanadze - BNP Paribas Exane Chris Pitcher - Redburn Operator Ladies and gentlemen, welcome to the Haleon Q1 2024 Trading Update Conference Call. I am Davin, the chorus call operator.

Haleon plc (HLN) Q1 2024 Earnings Call Transcript

Advil and Sensodyne maker Haleon PLC (LSE:HLN, NYSE:HLN) kept its full-year outlook unchanged as it reported lower first-quarter revenue, though this was in line with expectations. Organic revenues were 3.0% higher than the same quarter last year, with sales volumes and product mix provided a negative contribution of 2%, held back by a weaker cold and flu season, offset by 5% price growth.

Haleon revenues fall in first quarter

Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a surge last year.

Haleon's first-quarter revenue misses expectations

News that Sensoyde toothpaste maker Haleon PLC (LSE:HLN, NYSE:HLN) could cut around 435 jobs as part of the shuttering of an oral products manufacturing site has lifted the shares 1.5%. The FTSE 100 group, which was spun out of GSK two years ago, is planning to close a site in Maidenhead in the next two years.

Haleon eyes job cuts as UK manufacturing site 'no longer viable'

Consumer healthcare company Haleon is planning to shut down its manufacturing site in Britain by 2026, which will impact 435 jobs, a spokesperson told Reuters on Tuesday.

Sensodyne-maker Haleon to shut UK manufacturing site, with more than 400 jobs hit

Haleon is due to report its first-quarter earnings on 1 May with UBS upping its organic sales growth forecast to  3.2% from 3.0% previously. Comparatives are tough in Respiratory Health and Pain Relief but these will be offset by expected continued strong momentum in Oral Health, said the bank.

Haleon on course for sector leading earnings growth, analysts predict

One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker.

Haleon overhang can be gone in a year, suggests Barclays

Pfizer

Pfizer is raising around $4.27 billion from the sale of part of its stake in consumer-healthcare business Haleon.

Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale

Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping roughly £2.4 billion compared to the £2 billion expected, after the public offering was upsized.  The FTSE 100-listed consumer goods company said the US and international offer had been priced at £3.08 per ordinary share and $7.85 per American Depositary Shares.

Pfizer upsizes Haleon stake sale

Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising over £2 billion (US$2.55bn). Haleon, a former consumer health joint venture between GSK and Pfizer that was spun out in 2022, aims to but £315 million of the shares, it said.

Pfizer to sell down stake in Haleon

Consumer healthcare giant Haleon said on Monday that Pfizer will sell about 630 million of its shares in the company, reducing the US drugmaker's stake to about 24%.

Consumer healthcare giant Haleon says Pfizer to cut stake to 24%

AdaptHealth Corp

Investors interested in Medical - Products stocks are likely familiar with AdaptHealth Corp. (AHCO) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?

AHCO vs. HLN: Which Stock Should Value Investors Buy Now?

Haleon steadied the ship last week for consumer staples suppliers after a results shock from Reckitt Benckiser, according to analysts at Barclays. Indeed, Haleon is building a solid track record of organic growth and making rapid progress on deleverage and capital return, added the broker.

Haleon building 'solid track record,' says Barclays

Haleon plc (HLN) Q4 2023 Earnings Call Transcript

News for Haleon PLC Stock (HLN)